>
Switch to:

Altamira Therapeutics ROE %

: -72.59% (As of Jun. 2021)
View and export this data going back to 2014. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Altamira Therapeutics's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2021 was $-14.88 Mil. Altamira Therapeutics's average Total Stockholders Equity over the quarter that ended in Jun. 2021 was $20.50 Mil. Therefore, Altamira Therapeutics's annualized ROE % for the quarter that ended in Jun. 2021 was -72.59%.

The historical rank and industry rank for Altamira Therapeutics's ROE % or its related term are showing as below:

NAS:CYTO' s ROE % Range Over the Past 10 Years
Min: -4129.79   Med: -102.24   Max: -37.92
Current: -89.77

-4129.79
-37.92

During the past 10 years, Altamira Therapeutics's highest ROE % was -37.92%. The lowest was -4129.79%. And the median was -102.24%.

NAS:CYTO's ROE % is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: -68.79 vs. NAS:CYTO: -89.77 )

Altamira Therapeutics ROE % Historical Data

The historical data trend for Altamira Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.24 -423.35 -1,556.39 -137.43 -73.78

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.52 -81.08 -103.03 -105.80 -72.59

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics ROE % Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's ROE % falls into.



Altamira Therapeutics ROE % Calculation

Altamira Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-9.2300765420982/( (6.142886220232+18.876632147681)/ 2 )
=-9.2300765420982/12.509759183957
=-73.78 %

Altamira Therapeutics's annualized ROE % for the quarter that ended in Jun. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2021 )/( (Total Stockholders Equity (Q: Dec. 2020 )+Total Stockholders Equity (Q: Jun. 2021 ))/ count )
=-14.882132628332/( (18.876632147681+22.127120511126)/ 2 )
=-14.882132628332/20.501876329404
=-72.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is two times the semi-annual (Jun. 2021) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Altamira Therapeutics  (NAS:CYTO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-14.882132628332/20.501876329404
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.882132628332 / 0)*(0 / 24.778689126673)*(24.778689126673 / 20.501876329404)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.2086
=ROA %*Equity Multiplier
=N/A %*1.2086
=-72.59 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-14.882132628332/20.501876329404
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-14.882132628332 / -14.904163912756) * (-14.904163912756 / -14.223397224058) * (-14.223397224058 / 0) * (0 / 24.778689126673) * (24.778689126673 / 20.501876329404)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9985 * 1.0479 * N/A % * 0 * 1.2086
=-72.59 %

Note: The net income attributable to common stockholders data used here is two times the semi-annual (Jun. 2021) net income attributable to common stockholders data. The Revenue data used here is two times the semi-annual (Jun. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Altamira Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)